Structure Therapeutics (GPCR) Gains from Investment Securities (2022 - 2026)
Quarterly Gains from Investment Securities rose 388.69% to $4.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Mar 2026, changed N/A year-over-year, with the annual reading at $15.4 million for FY2025, 21.89% up from the prior year.
Structure Therapeutics' Gains from Investment Securities history spans 5 years, with the latest figure at $4.8 million for Q1 2026.
- Gains from Investment Securities came in at $4.8 million for Q1 2026, up from -$5.9 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $8.3 million in Q3 2023 to a low of -$5.9 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $679126.0 (2022), against an average of $1.5 million.
- The largest YoY upside for Gains from Investment Securities was 15309.61% in 2025 against a maximum downside of 279.11% in 2025.
- Structure Therapeutics' Gains from Investment Securities stood at $977000.0 in 2022, then skyrocketed by 301.43% to $3.9 million in 2023, then dropped by 16.27% to $3.3 million in 2024, then plummeted by 279.11% to -$5.9 million in 2025, then soared by 182.25% to $4.8 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Gains from Investment Securities are $4.8 million (Q1 2026), -$5.9 million (Q4 2025), and $67794.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.84 Mn |
| Mar 31, 2026 | 4.84 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Sep 30, 2025 | 67,794.00 |
| Sep 30, 2025 | 67,794.00 |
| Jun 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 990,000.00 |
| Mar 31, 2025 | 990,000.00 |
| Dec 31, 2024 | 3.28 Mn |
| Dec 31, 2024 | 3.28 Mn |
| Sep 30, 2024 | 25,794.00 |
| Sep 30, 2024 | 25,794.00 |
| Jun 30, 2024 | 25,794.00 |
| Jun 30, 2024 | 25,794.00 |
| Mar 31, 2024 | 381,252.00 |
| Mar 31, 2024 | 381,252.00 |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 8.27 Mn |
| Sep 30, 2023 | 8.27 Mn |
| Jun 30, 2023 | 236,000.00 |
| Jun 30, 2023 | 236,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Dec 31, 2022 | 977,000.00 |
| Dec 31, 2022 | 977,000.00 |